Introduction
Metastasis can be defined as the movement of a tumour cell from one site in the body to another separate site, where it grows independently. This process is insidious and progressive, every new site being a potential location from which further metastasis can occur. Eventually it leads to total destabilization, collapse of all the integrated control systems in the body, and death. The metastatic process is very complex and any prediction of progress depends on knowing the local microanatomy and microenvironment, the properties of the tumour cell involved and the extracellular structures and cells with which the tumour cell finally makes contact. Thus, by studying the interactions of the tumour cell membrane with the external environment, it may be possible to understand important steps in metastasis, and develop more effective means of therapeutic intervention.
The tumour cell membrane is decorated with many molecules that have carbohydrate Abbreviations used: ECM, extracellular matrix: GAG, glycosaminoglycan; HA, hyaluronan; sLe, sialylated Lewis antigen; LAMP, lysosome-associated membrane protein; HUVEC, human umbilical vein endothelial cell.
attached, and in some cases, this can be as much as 50% of the molecular mass. Furthermore there are large glycoconjugates in the extracellular environment that are loosely associated with tumour cells. The carbohydrate groupings on all these molecules are very variable, resulting in different glycoforms of the same molecule. This presents a massive array of biochemical forms that can affect the function of a molecule.
Evidence is accumulating from various studies on the importance of cell surface carbohydrate-mediated adhesive interactions in metastasis. These interactions can occur between carbohydrate and protein and possibly carbohydrate and carbohydrate. They are ideally suited for retaining the moving tumour cell when it comes into initial contact with another cell or the extracellular matrix (ECM). The affinity of these interactions is weak compared with proteinprotein interactions, but the sites of interaction are sufficiently numerous to have high avidity. They tether the moving tumour cell to allow it to make stronger linkages with other molecules, such as integrins, and so establish a stable base from which to initiate other biological processes, such as migration and growth.
The aim of this review is to explore the current state of knowledge on cell surface carboVolume 25
hydrate-mediated adhesive interactions in metastasis. The review is divided into three parts. In the first part, the details of three interactions are discussed; in the second part, evidence is discussed that suggests that these interactions are important in metastasis; and in the third part, our recent studies on the adhesion between the highly glycosylated protein CD44 on ovarian tumour cells and the glycosaminoglycan (GAG), hyaluronan (HA) are briefly described, which indicate that the avidity varies considerably between different tumour cell lines and is considerably influenced by the degree of glycosylation of CD44. Table 1 gives details of three types of interaction (E-selectin-sialyl Lewis antigens, CD44-HA, galactins-galactosides) involving cell surface glycoconjugates that could occur in the initial contact between the metastatic cell and the host. Other carbohydrate interactions (sialoadhesinssialic acid, glycolipid-glycolipid) may also occur, but the evidence for this is very limited (see ref.
Carbohydrate-mediated adhesive cell interactions
[l] for discussion). Each of the three well-documented interactions will now be discussed in detail.
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E-Selectin and Lewis antigens
E-Selectin (formerly ELAM-1) was discovered when monoclonal antibodies were raised against cell surface molecules on cultured endothelial cells activated with inflammatory mediators such as tumour necrosis factor and interleukin 1 [2].
These reagents were found to block the adhesion of granulocytic leucocytes to the activated endothelial cells and the molecule they recognized was ELAM-1. From molecular cloning studies and sequence analysis, it was found that ELAM-1 was a member of a family of three cell adhesion molecules that are found on leucocytes, endothelial cells or platelets. Because one domain of the molecules in this family was related to a larger group of proteins termed type-C lectins, it was likely that the counter-ligands for these molecules were carbohydrate moieties. The members of this family were subsequently named selectins. The major ligands for Eselectin are two tetrasaccharide antigens called sialyl LewisX and sialyl Lewisa, which are present at the end of oligosaccharide chains on glycoproteins, glycolipids and mucins [3]. These structures are characterized by the presence of CD44 is a cell surface adhesion molecule that is found on many cell types, including tumour cells [4] . It is a complex molecule that can exist in different forms. In its standard form, CD44H, which is very abundant on lymphocytes, it has a molecular mass of approx. 85-95 kDa. Glycosylation can account for up to 50% of the molecular mass as there are numerous sites for 0-and N-glycosylation. In addition to this extensive and variable glycosylation, CD44 can exist as protein isoforms. These variants are formed by the splicing of additional exons into the basic molecule. At least 18 CD44 transcripts have been described, with 12 of the 19 exons having the potential to undergo this alternative splicing. This leads to CD44 molecules that are three times the normal size. Some forms of CD44 can also have chondroitin sulphate attached. A major ligand for CD44 is the negatively charged high-molecular-mass HA [5] which is composed of the repeating disaccharide [Dglucuronic acid (/3 1-3) N-acetylglucosamine (/31-4)]". It exists as an expanded-coil structure in solution, with clustering of hydrophobic groups on the surface of the molecule producing a three-dimensional polymeric network. HA is found in association with other GAGS on the extracellular matrix of all tissues. It can also be attached to the cell surface by another receptor, and is present on some cells as a pericellular coat independent of a membrane receptor. Although the binding site for HA on CD44 is well characterized, many cells that express CD44 do not bind HA. Binding seems to be affected by the type of spliced variant involved and the type of gl ycosylation.
Galectins and galactosides
Galectins (formerly S-type lectins) are a family of proteins with an affinity for B-galactoside sugars, having a wide distribution in malignant and non-malignant tissues, but being particularly abundant in some tissues, for example, muscle, neurons, kidney and placenta [ 6 ] . Currently there are four well-characterized members of this group, galectins 1 and 2, which are homodimers, and galectins 3 and 4, which are larger molecules with no subunits. Galectins share common amino acid sequences in their carbohydrate-binding domain. Their molecular mass varies between 15 and 35 kDa. Although galectins do not have a typical secretion signal, they are found both in the cytoplasm and extracellularly, and in some cells, for example macrophages, they are in close association with the cell membrane. Despite the large number of B-galactosidecontaining glycoconjugates available, only a few bind to galectins. Glycoproteins that contain polylactosamines, such as the ECM component laminin, are good ligands. Galectin 1 has been reported to bind well to the polylactosaminerich lysosome-associated membrane proteins (LAMPS), which are sometimes present on the cell surface, and galectin 3 binds well to blood group A sugars. Their biological function is not completely defined, but evidence is accumulating for an important role in modulating cell adhesion.
Evidence for carbohydrate-mediated adhesive interactions in metastasis
A summary of the main lines of evidence for these interations having a role in metastasis is given in Table 2 . This evidence will now be discussed separately for each interaction.
E-Selectin and Lewis antigens
Very soon after the discovery of the interaction between the sLe antigens and E-selectin and its role in the adhesion of leucocytes to vascular endothelium, it became evident that a similar mechanism could be also operating in the metastatic spread of tumour cells. It was known that sLex, sLea and dimeric sLex were expressed at a high frequency in colonic cancers and that there was a correlation between increased expression of sLeX in the primary tumour and liver metastasis (see ref. [7] for discussion). A similar upregulation of sLeX in more aggressive disease was also reported for prostate [8] and lung cancer [9] . In another in v i m study it was shown that cancer cell lines that exhibited E-selectindependent adhesion to cytokine-activated human umbilical vein endothelial cells (HUVECs) were also dependent on the expression of either sLeX or sLea [lo] .
As liver metastases from colonic cancer express higher levels of sLeX than the primary tumour [7] , this suggests that cells that metastasize express more sLex. This idea was supported by the fact that a human colon carcinoma line Table 2 Evidence for carbohydrate-mediated adhesive interactions in metastatis 'Yes' means that the majority o f the studies support the conclusion stated; 'Yesmo' means that there are some studies that support the conclusion stated, but there are a significant proportion that do not; and "/A means that the information is not available. . T h e high expressor also showed greater adhesion to cytokine-activated HUVECs, and this adhesion was partially inhibited by an anti-E-selectin antibody.
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The increase in sLeX in colonic carcinoma appears to be mainly due to the more frequent addition of these moieties to mucins in the tumour tissue [ 121. Interestingly, patients with mucinous colorectal cancers have a worse prognosis than those with non-mucinous tumours [13] . Another study of human colonic cancer cell lines, however, showed that E-selectin can interact with both mucin and non-mucin ligands, whereas other selectins react only with mucin ligands [14] . A non-mucin source of sLe" on tumour cells could be LAMPs [15] . These are heavily glycosylated (55-60%) proteins that are normally found on lysosomes, but are sometimes found on the cell surface. Studies of human colonic carcinoma lines have shown that a variant that is highly metastatic to the liver in nude mice had more LAMP 1 and 2 than a low-metastatic variant [16] . In addition, the extent of adhesion to E-selectin and the expression of sLe" were proportional to the amount of cell surface LAMP 1 [17] . LAMPs have also been reported in breast cancer tissue [18] and on ovarian cancer cells 1191.
In order for circulating tumour cells to attach to vascular endothelium, they must be activated into expressing E-selectin. It seems likely that this activation is caused by tumour cells in combination with circulating inflammatory cells. Breast tumour cells can induce Eselectin on HUVECs and this was further enhanced if peripheral mononuclear cells were added [ZO] . In human colonic carcinomas, Eselectin was detected adjacent to nests of tumour cells and the degree of expression was inversely correlated with distance from the tumour [21] . Experiments with transgenic mice showed that the expression of cell surface E-selectin can redirect the metastatic cells from the lung to the liver if they express the appropriate ligand [22] .
CD44 and HA
T h e role of the CD44-HA interaction in the initial adhesion of metastatic cells is complex. Much of the interest in CD44 and metastasis stemmed from an early observation that showed that the transfer of certain variant exons of CD44 to a rat tumour line initiated metastasis [23] , but this idea of a metastatic gene has not been sustained. Although numerous studies of different tumour systems showed that increased CD44H and/or its spliced variants were associated with increased malignancy and poor prognosis (see ref. [23] for discussion), and it was assumed that these changes would alter the HA adhesion of the disseminated tumour cells, there are results from recent studies that do not support this hypothesis. The in vivo growth rate of human colonic cancer cell lines was inversely related to the binding to HA [24] . When the CD44 variant from the original transfection experiments was used with a different rat tumour, it was found to increase HA binding without changing the metastasis [25] . In a mouse lymphosarcoma in which CD44 was knocked out, the tumour was found to grow and metastasize as normal [26] .
Despite these conflicting data, it still seems likely that the CD44-HA interaction is involved in metastasis, but it may not be a critical factor in the progression of some tumours and/or in some situations. It is clear from previous work that there is not a simple correlation between the total amount of CD44 expressed on a cell and its interaction with HA [4] , and it may be difficult to interpret results from metastasis studies in terms of CD44-binding to HA. We have shown that the avidity of CD44 for HA varies considerably between different ovarian tumour lines [27] . One possible explanation for the discrepancy between CD44 expression and HA binding is the presence of CD44 spliced variants on tumour cells; some are known to bind HA at a reduced level [4] . However, this explanation cannot be true for some tumours because they do not express CD44 variants in high enough amounts to affect HA binding [28-301. As CD44 variants are detected in many normal tissues [31] , this also questions the importance of CD44 variants in cancer. As discussed below, the presence of spliced variants may have an indirect effect on HA binding through changes in glycosylation.
Recent studies have shown that the glycosylation of CD44 is important in affecting its interaction with HA. If N-acetylneuraminic acid is removed from cells with neuraminidase [32] , or cells are treated with tunicamycin (a drug that inhibits N-glycan formation) [32, 33] , this results in increased binding of CD44 to HA. On the other hand, inserting the heavily 0-glycosylated domain of mucin into the spliced variant region of CD44 substantially reduced HA binding [34] . As the glycosylation of a molecule varies with different cell types [35] , this would suggest that the glycosylation of CD44 varies between cell types and this would affect its interaction with HA. Recently, it was reported that CD44 isoforms that were transfected into CD44-negative lymphoma and fibroblastoid lines exhibited different HA-binding properties [36] .
Another factor to be considered in the interactions of CD44 with HA in metastasis is the location at which this interaction is occurring and what effect this might have on the overall process. Both reduced and increased CD44-HA interactions could promote certain steps in the metastatic process or vice versa. Reduced expression of CD44 in endometrial carcinoma was associated with the release of cells from the primary tumour into the lymph-vascular space [37] , and this change could promote metastasis. Similarly, ascites cells released into the peritoneal cavity from primary ovarian tumours had less CD44 than on normal cells [38] . On the other hand, many ovarian tumour lines express high levels of CD44 and bind strongly to mesothelial cells and immobilized HA [30, . Presumably, the reason that unbound cells in the ovariant ascites have such low levels of CD44 is because the cells with high levels have all bound to HA on the mesothelial lining of the peritoneal cavity.
Large amounts of HA on target cell membrane may not be required for interaction with tumour CD44. The adhesion of ovarian tumour cells to immobilized HA was detected for some lines at HA coating concentrations below 10 pg/ml [27] . Despite less than 1% of the GAGS synthesized by unstimulated HUVECs being HA [41] , an adhesive interaction that involved CD44-HA was reported for lymphoid cells when they were rolling over lymph node endothelial cells [42] .
Galactins and galactosides
Because the evidence for this type of interaction is more limited, it is not discussed separately for individual members of the galectin group. Surface expression of galectin 3 (formerly mac-2) in several tumour systems was previously found to be correlated with metastasis (see ref. [43] for discussion). In human tumours the situation is not so clear. Both increased [44] and decreased [45] galectin 3 were reported to be associated with metastasis, and normal human melanocytes and metastatic melanoma cells have similar levels of galectin 3 [46] . On the other hand, it was recently demonstrated that galectin 3 was greatly increased in human breast lines isolated from more metastatic tumours, but was not directly correlated with their invasive potential [43] .
Galectin interactions involving tumour cells can occur with other cell types, and between tumour cells and molecules present in the ECM. Volume 
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In the former case, the galectin can be on the tumour cell or the interacting cell. The adhesion of ovarian cancer cells to galectin 1 (formerly galaptin) was blocked by pretreating the tumour cells with antibodies to LAMP 1 and 2 [19] , whereas the adhesion of lymphoma cells to galectin 1 on hepatic sinusoidal endothelial cells or lung microvessel endothelial cells was blocked by treatment with anti-(galectin 1) antibodies [47] . Anti-(galectin 1) antibodies also blocked the binding of melanoma cells to laminin [48] . Also, the addition of soluble galectin 1 to melanoma cells increased their adhesion to laminin, which suggests that this galectin was acting as a glue in this case [48] . A similar type of interaction may be occurring with human breast cancer cells of low malignant potential, where addition of galectin 3 enhanced their migration through Matrigel [43] .
Adhesion of ovarian tumour cell to immobilized HA
The major step in the metastasis of ovarian cancer is the adhesion of cells that are shed from the primary tumour to a membrane (mesothelium) that covers omental and bowel surfaces in the peritoneal cavity. We developed a model to study this interaction by adding suspensions of ovarian tumour cells to mesothelial cells growing as a monolayer culture [49] . Using this system we discovered that the initial interaction that occurred was between CD44 on the tumour cells and HA on the mesothelial cells that is synthesized as a pericellular coat [39, 50] . In order to study this process in more detail and remove other factors that could interfere with the interaction, we simplified the system by measuring the adhesion of ovariant tumour cells to HA immobilized to plastic [30] . Table 3 summarizes the results that we obtained in these experiments, it also gives the CD44 expression for the four cell lines studied. It was found that the adhesion of these lines was not closely correlated with the magnitude of the CD44 expressed or the avidity of the CD44-HA interaction. There was also a large variation in avidity between the different ovarian tumour lines. However, when the cells were treated with neuraminidase to remove sialic acid, the adhesion of the two lines with the lowest avidity increased considerably. As might be expected, the adhesion of the other two lines was hardly changed. These findings are very important because they suggest that the avidity of carbohydrate-mediated interactions can be modulated by changes in the carbohydrate structure of one of the participants in the interaction. It also suggests that subtle changes in carbohydrate structure on tumour cells could influence the metastasis of ovarian cancer and this possibility might be further developed into new therapies. Table 3 Binding of ovarian tumour cells to immobilized HA RMF is the median fluorescence of cells incubated with anti-CD44 antibody divided by the median fluorescence of cells incubated with a control antibody. Cell adhesion was induced by adding fluorescently labelled cells to a multiwell plate that was precoated with I mg of HA/ml. After 5 min incubation, unbound cells were removed by washing and the fluorescence of the bound cells was measured. Avidity i s defined as the reciprocal of the range of HA coating concentrations (rng/rnl) over which the adhesion was approx. 50% of the maximum value. Cells were treated with 5 m-units of neuraminidase (Arthrobocter ureofaciens; Boehringer) for 30 min at 37°C before cell adhesion was measured. 
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Conclusions
There is good evidence for the involvement of tumour cell surface carbohydrate in adhesive interactions in metastasis. A number of different mechanisms are suggested by the currently available results, but further work is required to establish which mechanism is important in which tumour type at which stage of the process. It often appears that one mechanism predominates for one tumour type, for example, Eselectin-Lewis antigens for colorectal cancer and CD44-HA for ovarian cancer; however, the instability and variability of the tumour cell surface would suggest that multiple mechanisms may be involved. Because of the complexity of the situation in vivo, carbohydrate-mediated interactions in metastasis are best investigated using in vitro models. We have studied the binding of CD44 on ovarian tumour cells to immobilized HA and have shown that the avidity of the binding varies between different tumour lines and can be dramatically increased by removing sialic acid.
